These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 19013348)

  • 21. Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines.
    De Rosa FG; Motta I; Corcione S; Cattel F; Di Perri G; D'Avolio A
    Infez Med; 2014 Jun; 22(2):107-11. PubMed ID: 24955796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anidulafungin: a novel echinocandin for candida infections.
    de la Torre P; Meyer DK; Reboli AC
    Future Microbiol; 2008 Dec; 3(6):593-601. PubMed ID: 19072176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.
    Perkhofer S; Lass-Flörl C
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1393-404. PubMed ID: 19656074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
    Manfredi R; Sabbatani S
    Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on echinocandin antifungals.
    Kauffman CA; Carver PL
    Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echinocandins: pharmacokinetic and therapeutic issues.
    Cleary JD
    Curr Med Res Opin; 2009 Jul; 25(7):1741-50. PubMed ID: 19557937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
    Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
    Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candidemia in children.
    Zaoutis T
    Curr Med Res Opin; 2010 Jul; 26(7):1761-8. PubMed ID: 20513207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caspofungin: new indication. No progress in invasive candidiasis.
    Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current treatment of candidemia. Role of anidulafungin].
    Almirante B; Pemán J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():21-8. PubMed ID: 19572431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive candidiasis in the ICU: evidence based and on the edge of evidence.
    Hollenbach E
    Mycoses; 2008 Sep; 51 Suppl 2():25-45. PubMed ID: 18721330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungals in the ICU.
    Playford EG; Eggimann P; Calandra T
    Curr Opin Infect Dis; 2008 Dec; 21(6):610-9. PubMed ID: 18978529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The echinocandins: three useful choices or three too many?
    Bal AM
    Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH; Guglielmo BJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy of candidemia and invasive candidiasis according to guidelines].
    Glöckner A
    Mycoses; 2010 May; 53 Suppl 1():30-5. PubMed ID: 20433654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.
    Pea F
    Expert Rev Anti Infect Ther; 2013 Oct; 11(10):989-97. PubMed ID: 24093543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.